Is surgical indication in multiple myeloma a poor prognosis sign? SEER database analysis

被引:1
作者
Ozturk, Recep [1 ]
Amer, Kamil [2 ]
Gencoglu, Ayse Tugcenur [3 ]
Ozturk, Fatma Gokcenur [4 ]
Kasali, Kamber [5 ]
Aytekin, Mahmut Nedim [6 ]
机构
[1] Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Orthoped & Traumatol, TR-06200 Ankara, Turkiye
[2] Thomas Jefferson Univ Hosp, Rothman Orthoped Inst, Orthoped, Philadelphia, PA USA
[3] Ankara Haymana State Hosp, Internal Med, Ankara, Turkiye
[4] Kecioren Dist Hlth Directorate, Family Med, Ankara, Turkiye
[5] Ataturk Univ, Dept Biostat, Erzurum, Turkiye
[6] Ankara Yildirim Beyazit Univ, Orthoped & Traumatol, Ankara, Turkiye
关键词
Plasma cell myeloma; Multiple myeloma; Cancer; Overall survival; Surgery; MANAGEMENT;
D O I
10.1007/s12094-023-03273-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
AimThis study aims to investigate demographic data, survival rates, and the relationship of these rates with surgery in a large case series including multiple myeloma (MM) patients.MethodMM cases were analyzed retrospectively using the latest version of the SEER database published in April 2020. This version covers January 1975 to December 2017. Patients were classified according to gender, age, and race/ethnicity. Tumors were classified according to their localization, grade, year of diagnosis, and follow-up results.ResultsThere were 60,239 patients diagnosed with Plasma Cell Myeloma. While 670 patients (1.2%) were operated on, 43,976 patients (76.7%) did not indicate operation, and 12,670 patients (22.1%) could not be operated on despite the recommendation. The mean survival was 62 months in those without an indication for surgery, and 42 months in patients with an indication but could not be operated on, and the difference was significant (p = 0.001). The mean survival was 58 months in the operated patients, and 42 months in the patients who could not be operated on despite the indication, and the difference was significant (p = 0.001). There was no difference between those who did not indicate surgery and those who were operated on with an indication (p = 0.243).ConclusionIn multiple myeloma, the best prognosis is in the group of patients who received medical treatments without any indication for operation, while an indication for operation indicates a worse prognosis. A worse prognosis should be expected in patients who do not accept the operation or who cannot be operated on compared to the operated patients.
引用
收藏
页码:524 / 531
页数:8
相关论文
共 19 条
[1]   Epidemiology, incidence, and survival of synovial sarcoma subtypes: SEER database analysis [J].
Aytekin, Mahmut Nedim ;
Ozturk, Recep ;
Amer, Kamil ;
Yapar, Aliekber .
JOURNAL OF ORTHOPAEDIC SURGERY, 2020, 28 (02)
[2]   Epidemiological Study of Adamantinoma from US Surveillance, Epidemiology, and End Results Program: III Retrospective Analysis [J].
Aytekin, Mahmut Nedim ;
Ozturk, Recep ;
Amer, Kamil .
JOURNAL OF ONCOLOGY, 2020, 2020
[3]   Multiple myeloma: Primary bone tumor with systemic manifestations [J].
Bilsky, Mark H. ;
Azeem, Syed .
NEUROSURGERY CLINICS OF NORTH AMERICA, 2008, 19 (01) :31-+
[4]  
Cancerdata, 2020, About us
[5]   Consensus on Surgical Management of Myeloma Bone Disease [J].
Du, Xin-ru .
ORTHOPAEDIC SURGERY, 2016, 8 (03) :263-269
[6]   The Diagnosis and Treatment of Multiple Myeloma [J].
Gerecke, Christian ;
Fuhrmann, Stephan ;
Strifler, Susanne ;
Schmidt-Hieber, Martin ;
Einsele, Hermann ;
Knop, Stefan .
DEUTSCHES ARZTEBLATT INTERNATIONAL, 2016, 113 (27-28) :470-+
[7]   Oncological and functional results of the surgical treatment of vertebral metastases in patients with multiple myeloma [J].
Guzik, Grzegorz .
BMC SURGERY, 2017, 17
[8]   Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients [J].
Kumar, S. K. ;
Dispenzieri, A. ;
Lacy, M. Q. ;
Gertz, M. A. ;
Buadi, F. K. ;
Pandey, S. ;
Kapoor, P. ;
Dingli, D. ;
Hayman, S. R. ;
Leung, N. ;
Lust, J. ;
McCurdy, A. ;
Russell, S. J. ;
Zeldenrust, S. R. ;
Kyle, R. A. ;
Rajkumar, S. V. .
LEUKEMIA, 2014, 28 (05) :1122-1128
[9]   Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes [J].
Landgren, O. ;
Iskander, K. .
JOURNAL OF INTERNAL MEDICINE, 2017, 281 (04) :365-382
[10]  
Milano Anthony F, 2018, J Insur Med, V47, P203, DOI 10.17849/insm-47-04-1-9.1